Sequential CAR-T cells for advanced ovarian cancer with CD146 and GPC3
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced ovarian cancer (including fallopian tube or primary peritoneal cancer) that has come back or stopped responding to standard treatments, including at least one platinum-based chemotherapy.
- A recent tumor sample shows your cancer cells have two specific proteins, CD146 and GPC3 (this is checked by a special lab test).
- You are at least 18 years old, in generally good health (ECOG performance status 0 or 1), and have adequate organ function (liver, kidneys, bone marrow).
- You have at least one tumor that can be measured on a CT scan or other imaging.
- You have not had any prior CAR-T cell therapy targeting CD146 or GPC3, and you do not have active brain metastases, uncontrolled infections, or other serious medical conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune therapy called CAR T-cells (SCT-001) for ovarian cancer that has returned or isn't responding to standard treatments. The cells are engineered to find and attack cancer cells that have a specific marker (TAG-72) on their surface.
This trial tests a new treatment called CAR-T cells that target a protein called B7H3 found on cancer cells. It is for people with a specific type of ovarian, peritoneal, or fallopian tube cancer that has not responded well to platinum chemotherapy or has come back quickly.
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
This Phase 1/2 study tests a personalized immune-cell treatment (fully human B7H3 CAR-T) for ovarian cancer that has come back or did not respond. It aims to see whether CAR-T can attack tumors that carry a target called B7H3.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests a new treatment using your own immune cells (CAR-T cells) designed to attack cancer cells that have a protein called CD70. It is for people with advanced solid tumors that have not responded to standard treatments.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.